Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis.

BioMed research international - 1 Jan 2020

Wang Shu, Liu Mingyue, Lian Siheng, Liu Naiming, Zhang Guibin, Zhao Qingchun, Zhang Yingshi, Jian Lingyan

Abstract excerpt

OBJECTIVE: The phosphatidylinositol 3-kinase (PI3K) signaling pathway is a promising treatment target for patients with breast cancer (BC). Our study aimed to evaluate the most effective and safe PI3K inhibitor for patients with BC, especially in PIK3CA mutation. METHODS: Electronics databases were systematically searched from their inception to June 2020 for published randomized controlled trials (RCTs)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Morpholines

Share to Phosphatidylinositol 3-Kinases

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Progression-Free Survival

Share to Thiazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 33376736
DOI: 10.1155/2020/7451576
PMCID: PMC7739049

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis.PMID 33376736Read ↗

Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway.Semantic proximity Read ↗

Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical ChallengesSemantic proximity Read ↗

Strategies and techniques for preclinical therapeutic targeting of PI3K in oncology: where do we stand in 2024?Semantic proximity Read ↗

Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current AchievementsSemantic proximity Read ↗

Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer.Semantic proximity Read ↗

PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance.Semantic proximity Read ↗

PIK3CA somatic alterations in invasive breast cancers: different spectrum from Caucasians to Chinese detected by next generation sequencing.Semantic proximity Read ↗

The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis.Semantic proximity Read ↗

Prognostic role of PIK3CA mutations and their association with hormone receptor expression in breast cancer: a meta-analysis.Semantic proximity Read ↗

A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR+/HER2- Metastatic Breast Cancer.Semantic proximity Read ↗

The Predictive Role of PIK3CA Mutation Status on PI3K Inhibitors in HR+ Breast Cancer Therapy: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Survival analysis of patients with early breast cancer associated with PIK3CA mutationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.